Compare Colgate-Palmolive Company (CL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs Illumina, Inc. — how do they compare? Colgate-Palmolive Company trades at $92.22 (market cap $74.26B), while Illumina, Inc. trades at $193.06 (market cap $28.96B). The key difference: Colgate-Palmolive Company is far larger — about 2.6× Illumina, Inc.'s market cap, and Colgate-Palmolive Company pays a 2.28% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| CL | ILMN | |
|---|---|---|
Market Cap | $74.26B | $28.96B |
Sector | Consumer Staples | Health |
52-Week High | $99.14 | $205.10 |
52-Week Low | $74.98 | $91.00 |
Enterprise Value | $80.74B | $30.32B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.27, up 0.29% on the day, with a bullish technical signal and consistent earnings beats. The company reported Q2 2026 EPS of $0.99, exceeding estimates, driven by strong margins and organic growth in emerging markets, though North American performance remains weak. Operating cash flow remains robust at $4.2 billion in 2025, supporting shareholder returns.
Outlook is mixed: valuation appears stretched with a P/E of 36.72, but analyst consensus targets $99.10. Risks include competitive pressures in North America and high debt levels. The stock offers a stable dividend, but growth concerns and insider selling warrant caution.
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
